Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer

NCT00398086 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00398086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00398086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial of Gemcitabine (Gemzar) Plus ABI-007 (ABRAXANE) In Patients With Advanced Metastatic Pancreatic Cancer
Lead sponsor
Celgene
Phase
Phase 1/2
Overall status
Completed
Start date
November 1, 2006
Completion date
December 1, 2010
Enrollment
67 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer